PLoS ONE (Jan 2022)

Interleukin-1β triggers matrix metalloprotease-3 expression through p65/RelA activation in melanoma cells.

  • Junichi Nunomura,
  • Rei Nakano,
  • Atsuto Naruke,
  • Yoko Suwabe,
  • Masumi Nakano,
  • Naoya Yachiku,
  • Manami Kuji,
  • Mana Sugimura,
  • Shinichi Namba,
  • Taku Kitanaka,
  • Nanako Kitanaka,
  • Hiroshi Sugiya,
  • Tomohiro Nakayama

DOI
https://doi.org/10.1371/journal.pone.0278220
Journal volume & issue
Vol. 17, no. 11
p. e0278220

Abstract

Read online

Melanoma shows highly aggressive behavior (i.e., local invasion and metastasis). Matrix metalloprotease-3 (MMP-3), a zinc-dependent endopeptidase, degrades several extracellular substrates and contributes to local invasion by creating a microenvironment suitable for tumor development. Here, we report that interleukin-1β (IL-1β) triggers the MMP-3 expression in canine melanoma cells. The activity of MMP-3 in the culture supernatant was increased in IL-1β-treated melanoma cells. IL-1β time- and dose-dependently provoked the mRNA expression of MMP-3. IL-1β induced the migration of melanoma cells; however, this migration was attenuated by UK356618, an MMP-3 inhibitor. When the cells were treated with the nuclear factor-κB (NF-κB) inhibitor TPCA-1, the inhibition of MMP-3 expression was observed. In IL-1β-treated cells, the phosphorylation both of p65/RelA and p105 was detected, indicating NF-κB pathway activation. In p65/RelA-depleted melanoma cells, IL-1β-mediated mRNA expression of MMP-3 was inhibited, whereas this reduction was not observed in p105-depleted cells. These findings suggest that MMP-3 expression in melanoma cells is regulated through IL-1β-mediated p65/RelA activation, which is involved in melanoma cell migration.